

# Tumores Neuroendócrinos

## **Adriamicina + Estreptozotocina**

Adriamicina: 50 mg/m<sup>2</sup> IV D1 e 22

Estreptozotocina: 500 mg/m<sup>2</sup>/dia IV D1–5

cada 6 semanas

Ref. (1)

## **EP**

Cisplatina: 45 mg/m<sup>2</sup>/dia IV por infusão contínua D2 e D3

Etoposide: 130 mg/m<sup>2</sup>/dia IV por infusão contínua nos D1–3

a cada 21 dias

Ref. (2)

## **EP**

Etoposide: 100 mg/m<sup>2</sup> IV D1-3

Cisplatina: 25 mg/m<sup>2</sup> IV D1-3

a cada 21 dias

Ref. (3)

## **Carboplatina + radioterapia**

Carboplatina: AUC 2, semanal, durante radioterapia

Ref. (6)

## **Octreotide**

Octreotide: 150–250 µg SC uma a três vezes por dia

Ref. (4)

Octreotide LAR: 20 a 40 mg IM 1x/mês

Ref. (5)

## **5-Fluorouracil + Octreotide**

5-Fluorouracil: 200mg/m<sup>2</sup> IV diariamente

Octreotide LAR: 20mg IM mensalmente

Ref. (7)

## **Everolimo + Octreotide**

Everolimo: 5 a 10mg/dia VO

Octreotide LAR: 30mg/mês IM

Ref. (8)

## **PCE**

Paclitaxel: 200mg/m<sup>2</sup> IV em 1 hora D1

Carboplatina: AUC 6 IV D1

Etoposide VO alternando 50mg e 100mg diariamente, D1 a D10  
a cada 21 dias Ref. (10)

## **Irinotecano + Cisplatina**

Irinotecano: 65mg/m<sup>2</sup> IV D1 e D8

Cisplatina: 30mg/m<sup>2</sup> IV D1 e D8

a cada 21 dias Ref. (11)

## **Temozolamida + Talidomida**

Temozolamida: 150mg/m<sup>2</sup> VO por 7 dias, a cada 15 dias

Talidomida: 50 a 400mg VO diariamente. Ref. (12)

## **Etoposide e Carboplatina associado a Radioterapia**

Etoposide: 80mg/m<sup>2</sup> D1 a D3 IV

Carboplatina: AUC 4.5 IV

Semanas 1, 4, 7 e 10 Ref. (13)

## **FDE**

Fluorouracil: 500mg/m<sup>2</sup> IV D1 a D3

Dacarbazina: 200mg/m<sup>2</sup> IV D1 a D3

Epirrubicina: 30mg/m<sup>2</sup> IV D1 a D3

a cada 21 dias Ref. (14)

## **Interferon alpha 2a**

Interferon 6 x 10<sup>6</sup> UI diariamente x 8 semanas, seguido por 6 x  
10<sup>6</sup> UI, três vezes por semana Ref. (15)

## **Everolimo**

10 mg VO dia uso contínuo Ref. (16)

1. Moertel CG, *et al.* Streptozocin-Adriamicina, streptozocin-fluorouracil, or chlorozotocin in the treatment of advanced islet-cell carcinoma. *N Engl J Med* 1992;326:519–526.

2. Moertel CG, *et al.* Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. *Cancer* 1991;68:227–232.
3. Longeval E, *et al.* Combination chemotherapy with cisplatin and etoposide in bronchogenic squamous cell carcinoma adenocarcinoma. A study by the EORTC lung cancer working party. *Cancer*. 1982; 50:2751–2756.
4. Saltz L, *et al.* Octreotide as an antineoplastic agent in the treatment of functional and nonfunctional neuroendocrine tumors. *Cancer* 1993;72:244.
5. Rubin J. *et al.* Octreotide Acetate Long-Acting Formulation Versus Open-Label Subcutaneous Octreotide Acetate in Malignant Carcinoid Syndrome. *J Clin Oncol* 17:600, 1999.
6. Poulsen M, Walpole E, Harvey J, Dickie G, O'Brien P, Keller J, Tripcony L, Rischin D. Weekly carboplatin reduces toxicity during synchronous chemoradiotherapy for Merkel cell carcinoma of skin. *Int J Radiat Oncol Biol Phys*. 2008 Nov 15;72(4):1070-4.
7. Brizzi MP, Berruti A, Ferrero A, Milanese E, Volante M, Castiglione F, Birocco N, Bombaci S, Perroni D, Ferretti B, Alabiso O, Ciuffreda L, Bertetto O, Papotti M, Dogliotti L. Continuous 5-fluorouracil infusion plus long acting octreotide in advanced well-differentiated neuroendocrine carcinomas. A phase II trial of the Piemonte oncology network. *BMC Cancer*. 2009 Nov 3;9:388.
8. Yao JC, Phan AT, Chang DZ, Wolff RA, Hess K, Gupta S, Jacobs C, Mares JE, Landgraf AN, Rashid A, Meric-Bernstam F. Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study *J Clin Oncol*. 2008 Sep 10;26(26):4311-8. ERRATUM *J Clin Oncol*. 2008 Dec 1; 26 (34) 5660.
10. Hainsworth JD, Spigel DR, Litchy S, Greco FA. Phase II trial of paclitaxel, carboplatin, and etoposide in advanced poorly differentiated neuroendocrine carcinoma: a Minnie Pearl Cancer Research Network Study. *J Clin Oncol*. 2006 Aug 1; 24(22):3548-54.

- 11.** Kulke MH, Wu B, Ryan DP, Enzinger PC, Zhu AX, Clark JW, Earle CC, Michelini A, Fuchs CS. A phase II trial of irinotecan and cisplatin in patients with metastatic neuroendocrine tumors. *Dig Dis Sci*, 2006 Jun;51(6): 1033-8.
- 12.** Kulke MH, Stuart K, Enzinger PC, Ryan DP, Clark JW, Muzikansky A, Vincitore M, Michelini A, Fuchs CS. Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors. *J Clin Oncol*. 2006 Jan 20;24(3):401-6.
- 13.** Poulsen M, Rischin D, Walpole E, Harvey J, Mackintosh J, Ainslie J, Hamilton C, Keller J, Tripcony L; Trans-Tasman Radiation Oncology Group High-risk Merkel cell carcinoma of the skin treated with synchronous carboplatin/etoposide and radiation: a Trans-Tasman Radiation Oncology Group Study--TROG 96:07. *J Clin Oncol*. 2003 Dec 1;21(23):4371-6.
- 14.** Bajetta E, Rimassa L, Carnaghi C, Seregni E, Ferrari L, Di Bartolomeo M, Regalia E, Cassata A, Procopio G, Mariani L. 5-Fluorouracil, dacarbazine, and epirubicin in the treatment of patients with neuroendocrine tumors. *Cancer*. 1998 Jul 15; 83(2):372-8.
- 15.** Bajetta E, Zilembo N, Di Bartolomeo M, Di Leo A, Pilotti S, Bochicchio AM, Castellani R, Buzzoni R, Celio L, Dogliotti L, *et al*. Treatment of metastatic carcinoids and other neuroendocrine tumors with recombinant interferon-alpha-2a. A study by the Italian Trials in Medical Oncology Group. *Cancer*. 1993 Nov 15;72(10):3099-105.
- 16.** Yao, James C. M.D.; Shah, Manisha H. M.D.; Ito, Tetsuhide M.D. *et. al*. Everolimus for Advanced Pancreatic Neuroendocrine Tumors. *N Engl J Med*. 2011; 364 (6): 514-523.